Baxter International Inc at Morgan Stanley Global Healthcare Conference Transcript
Great. Thanks, everyone, for joining another session at the conference. I'm Drew Ranieri, one of the medical device analysts here. And it's my absolute pleasure to have Baxter International with us today, CFO, Jay Saccaro; and VP of Investor Relations, Clare Trachtman.
Before we go into Q&A, just to highlight the disclosure, but for important disclosures, please see the Morgan Stanley research disclosure website. And if you have any questions, reach out to your Morgan Stanley sales rep.
Questions & Answers
So Jay, on to Q&A, and thank you again for being here. And kind of with the rumor that came out last night about potential asset sales, I know you won't necessarily comment on it specifically, but I mean, there has been a lot happening in the renal space from the corporate action side in 2022 on top of some government regulatory positive changes in targeting, moving care into
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |